© 2026 社團法人國家生技醫療產業策進會 & 財團法人生技醫療科技政策研究中心 版權所有
2025-11-19
The 9th Healthcare Expo Taiwan will be held at Taipei Nangang Exhibition Center, Hall 1 from December 4th to 7th, expecting nearly 40 overseas industry associations to visit Taiwan in search of collaboration opportunities with Taiwan’s medical and biotechnology sectors. Ahead of the event, the organizers have launched a special “International Associations Interview Series,” featuring first-time visiting representatives who share their perspectives on Taiwan’s market potential and cooperation opportunities, helping domestic companies prepare for early business matchmaking.
Taiwan’s generic drug industry has advanced significantly in recent years — improving in quality, technology, and manufacturing capabilities while meeting international GMP and PIC/S standards. The nation has become a competitive pharmaceutical manufacturing hub combining high quality with cost efficiency.
In this context, the Expo organizing committee invited Dr. Luka Prosdocimo, Deputy Director of Medicines for Europe, the largest generic medicine association, to visit Taiwan for the first time. In an exclusive pre-show interview, Dr. Prosdocimo praised Taiwan’s strong performance in API and finished drug manufacturing, noting that amid Europe’s efforts to diversify its supply chains, Taiwan stands out as a highly promising partner.
A Core Organization Representing 70% of Europe’s Medicine Supply
Founded in 1993, Medicines for Europe—formerly known as the European Generic Medicines Association (EGA)—is the largest association representing Europe’s generic, biosimilar, and value-added medicine (VAM) industries. The organization advocates affordable and equitable access to medicines, while maintaining innovation and competitiveness across the European pharmaceutical market.
Its membership spans the EU and the UK, covering 90 leading pharmaceutical companies, including Biogen, Sandoz, Teva, and Fresenius Kabi. Together, these members operate over 400 manufacturing sites and 126 R&D centers, employ approximately 190,000 people, and supply more than 70% of all medicines in Europe.
Building Connections — Introducing Taiwan’s Manufacturers to Europe
Dr. Prosdocimo stated that one key mission of this visit is to collect information on Taiwan’s pharmaceutical capabilities and share the profiles of local companies with European members to facilitate potential cooperation.
“We’re identifying Taiwanese CDMO and API companies with compliance experience, audit records, or existing exports to the EU and U.S. markets,” he explained.
“We invite them to provide company profiles, product portfolios, and capacity details. These will be compiled and distributed to our members to help explore partnership opportunities.”
This marks Medicines for Europe’s first systematic engagement with Taiwan’s pharmaceutical sector, and Dr. Prosdocimo expressed hope that this trip will lay the foundation for long-term cooperation between the two sides.
EU’s “Critical Medicines Act” Creates New Opportunities for Taiwanese Companies
Dr. Prosdocimo noted that Medicines for Europe is actively promoting the Critical Medicines Act, a new EU legislative initiative designed to strengthen Europe’s manufacturing capacity, improve supply chain resilience, and ensure the stable supply of essential medicines through collaboration with external partners such as Taiwan.
He highlighted that Taiwan’s CDMO and API manufacturers, known for their world-class quality standards, stable production capacity, and flexible operations, are well-positioned to become strategic suppliers for Europe. Companies with EU or U.S. GMP inspection approvals will have particularly strong opportunities for partnership under this framework.
ESG and Sustainability Standards on the Rise — Taiwan Should Prepare Early
Dr. Prosdocimo also cautioned that European pharmaceutical companies are placing increasing emphasis on ESG performance. The EU is preparing to introduce a mandatory supply chain due diligence framework, which will require all partners to comply with stricter environmental, safety, and sustainability standards.
He encouraged Taiwanese manufacturers to align early with these new expectations to ensure readiness for long-term collaborations with European partners.